A Cancer Research UK Phase I Trial of AZD3965, a monocarboxylate transporter 1 inhibitor (MCT1) in patients with advanced cancer

Next Previous
Trial Profile

A Cancer Research UK Phase I Trial of AZD3965, a monocarboxylate transporter 1 inhibitor (MCT1) in patients with advanced cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs AZD 3965 (Primary)
  • Indications Diffuse large B cell lymphoma; Gastric cancer; Lymphoma; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (n=35) assessing the maximum tolerated dose of in AZD3965 in patients with advanced solid tumours, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 04 Dec 2013 Accrual to date is 9% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top